Advanced in Rhabdoid Tumor Predisposition Syndrome

Dr. Sagus Sampath

Radiation Oncology
City Of Hope Medical Foundation
1500 E Duarte Rd, 
Duarte, CA 
Offers Telehealth
Advanced in Rhabdoid Tumor Predisposition Syndrome
City Of Hope Medical Foundation
1500 E Duarte Rd, 
Duarte, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sagus Sampath is a Radiation Oncologist in Duarte, California. Dr. Sampath is rated as an Advanced provider by MediFind in the treatment of Rhabdoid Tumor Predisposition Syndrome. His top areas of expertise are Lung Cancer, Adult Soft Tissue Sarcoma, Bone Tumor, Pleuropulmonary Blastoma, and Prostatectomy.

His clinical research consists of co-authoring 45 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Radiation Oncology
Licenses
Radiology in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

CITY OF HOPE MEDICAL FOUNDATION
1500 E Duarte Rd, Duarte, CA 91010
Other Locations
CITY OF HOPE MEDICAL FOUNDATION
209 Fair Oaks Ave, South Pasadena, CA 91030
CITY OF HOPE MEDICAL FOUNDATION
1500 Duarte Rd, Duarte, CA 91010

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Procedure, Drug, Biological, Radiation
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 2/Phase 3
Phase 1 Trial to Determine the Recommended Phase 2 Dose (RP2D) of M6620 (VX-970, Berzosertib) When Combined With Whole Brain Radiotherapy (WBRT) in Patients With Brain Metastases From Lung Cancer
Phase 1 Trial to Determine the Recommended Phase 2 Dose (RP2D) of M6620 (VX-970, Berzosertib) When Combined With Whole Brain Radiotherapy (WBRT) in Patients With Brain Metastases From Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2025
Intervention Type: Other, Radiation, Drug, Procedure
Study Drug: Berzosertib
Study Phase: Phase 1
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
A Phase I Study of M6620 (VX-970, Berzosertib) in Combination With Cisplatin and XRT in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC; SDC 10060121)
A Phase I Study of M6620 (VX-970, Berzosertib) in Combination With Cisplatin and XRT in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC; SDC 10060121)
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Procedure, Drug, Other, Radiation
Study Drugs: Berzosertib, Cisplatin
Study Phase: Phase 1
A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma
A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2025
Intervention Type: Procedure, Biological, Radiation
Study Drug: Talimogene Laherparepvec
Study Phase: Phase 2
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Enrollment Status: Active_not_recruiting
Publish Date: March 11, 2025
Intervention Type: Radiation, Drug
Study Drugs: Docetaxel, Gemcitabine, Pemetrexed Disodium, Erlotinib Hydrochloride, Pembrolizumab
Study Phase: Phase 2
Stereotactic Body Radiation Therapy to the Prostate Fossa: Phase I Dose Escalation Study
Stereotactic Body Radiation Therapy to the Prostate Fossa: Phase I Dose Escalation Study
Enrollment Status: Active_not_recruiting
Publish Date: February 05, 2025
Intervention Type: Procedure, Other, Radiation
Study Phase: Phase 1
A Phase II, Open Label, Multi-Dose Study of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients With Selected Advanced or Metastatic Solid Malignancies Who Are Scheduled to Receive Standard-of-Care Immunotherapy Only, As Single Agent or in Combination
A Phase II, Open Label, Multi-Dose Study of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients With Selected Advanced or Metastatic Solid Malignancies Who Are Scheduled to Receive Standard-of-Care Immunotherapy Only, As Single Agent or in Combination
Enrollment Status: Completed
Publish Date: July 09, 2024
Intervention Type: Drug
Study Drug: 89Zr-Df-IAB22M2C
Study Phase: Phase 2
View 7 Less Clinical Trials

45 Total Publications

Evaluating Clinical Factors Including HPV Clearance on Survival Outcomes in HPV+ Oropharyngeal Carcinoma.
Evaluating Clinical Factors Including HPV Clearance on Survival Outcomes in HPV+ Oropharyngeal Carcinoma.
Journal: Cancers
Published: July 08, 2025
Similar Doctors
Advanced in Rhabdoid Tumor Predisposition Syndrome
Dr. Jeremy P. Harris
Radiation Oncology
Advanced in Rhabdoid Tumor Predisposition Syndrome
Dr. Jeremy P. Harris
Radiation Oncology

Uc Regents Department Of Radiation Oncology

101 The City Dr S, 
Orange, CA 
 (24.0 miles away)
714-456-5508
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jeremy Harris is a Radiation Oncologist in Orange, California. Dr. Harris is rated as an Advanced provider by MediFind in the treatment of Rhabdoid Tumor Predisposition Syndrome. His top areas of expertise are Lung Cancer, Bone Tumor, Alveolar Soft Part Sarcoma, and Rhabdomyosarcoma.

Advanced in Rhabdoid Tumor Predisposition Syndrome
Dr. Peyman Kabolizadeh
Radiation Oncology
Advanced in Rhabdoid Tumor Predisposition Syndrome
Dr. Peyman Kabolizadeh
Radiation Oncology

Memorial Radiation Oncology Medical

18111 Brookhurst St, Ll0300, 
Fountain Valley, CA 
 (29.6 miles away)
714-962-7100
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Peyman Kabolizadeh is a Radiation Oncologist in Fountain Valley, California. Dr. Kabolizadeh is rated as a Distinguished provider by MediFind in the treatment of Rhabdoid Tumor Predisposition Syndrome. His top areas of expertise are Anal Cancer, Breast Cancer, Adult Soft Tissue Sarcoma, and Rhabdomyosarcoma Embryonal. Dr. Kabolizadeh is currently accepting new patients.

Experienced in Rhabdoid Tumor Predisposition Syndrome
Dr. Behrooz Hakimian
Radiation Oncology
Experienced in Rhabdoid Tumor Predisposition Syndrome
Dr. Behrooz Hakimian
Radiation Oncology
8700 Beverly Boulevard, Suite AC1010, 
Los Angeles, CA 
 (23.6 miles away)
310-423-4204
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Behrooz Hakimian is a Radiation Oncologist in Los Angeles, California. Dr. Hakimian is rated as a Distinguished provider by MediFind in the treatment of Rhabdoid Tumor Predisposition Syndrome. His top areas of expertise are Posterior Fossa Tumor, Meningioma, Radiation Induced Meningioma, and Primitive Neuroectodermal Tumor (PNET). Dr. Hakimian is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sampath's expertise for a condition
ConditionClose
    View All 22 Distinguished Conditions
    View All 29 Advanced Conditions
    View All 29 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile